EX-10.2
from 10-Q
4 pages
For Good and Valuable Consideration, the Receipt and Sufficiency of Which Are Hereby Acknowledged by Celator Pharmaceuticals, Inc., a Delaware Corporation (The “Company”), the Company Hereby Grants to Hercules Technology Growth Capital, Inc., a Maryland Corporation (“Hercules”), the Right to Participate in and/or Designate One or More of Its Affiliates (Hercules, Together With Such Affiliates, Collectively, “Hercules Purchasers”) to Participate in Any One or More Subsequent Financings (As Defined Below) of the Company Selected by Hercules in Its Sole Discretion by Permitting All Hercules Purchasers Who Participate in Such Subsequent Financings to Purchase Up to a Maximum Aggregate (For All Subsequent Financings) of $2,000,000 of Subsequent Financing Securities (As Defined Below) Therein. Hercules Purchasers Shall Have No Obligation to Purchase Subsequent Financing Securities in Any Subsequent Financing. Each Hercules Purchaser Purchasing Subsequent Financing Securities Shall Be an “Accredited Investor” as Defined in Regulation D Promulgated Under the Securities Act of 1933, as Amended (The “Act”). as Used Herein
12/34/56
